On this page

Clotrimazole Topical Solution USP, 1%

Prescription ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Clotrimazole Topical Solution USP, 1%
Generic name
Clotrimazole Topical Solution USP, 1%
Dosage form
Solution
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Allegis Holdings, LLC
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
5
Packages
8
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Clotrimazole 10 mg/mL 308714 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Solution
Route of administration
Topical
Presentations
13

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Azole Antifungal [EPC] EPC All 44 members
Azoles [CS] CS All 44 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
216569
Application type
ANDA · Abbreviated New Drug Application
Approval date
October 16, 2023
Sponsor
SCIEGEN PHARMS
Products on application
1
Submissions recorded
1
Products approved under application 216569.
Product Trade name Form Strength Ingredient Status TE Flags
216569-001 CLOTRIMAZOLE SOLUTION CLOTRIMAZOLE Prescription AT

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 216569.
Type No. Action Status Date Review
Original application 1 Approved October 16, 2023 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260430). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260430 HUMAN PRESCRIPTION DRUG · 20260118 HUMAN PRESCRIPTION DRUG · 20241020

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Prescription Clotrimazole Topical Solution product is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . This formulation is also available as a nonprescription product which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes , Epidermophyton fluoccosum , and Microsporum canis .

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Gently massage sufficient clotrimazole topical solution USP, 1% into the affected and surrounding skin areas twice a day, in the morning and evening. Clinical improvement, with relief of pruritus, usually occurs within the first week of treatment with clotrimazole topical solution USP, 1%. If the patient shows no clinical improvement after 4 weeks of treatment with clotrimazole topical solution USP, 1%, the diagnosis should be reviewed.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Topical antifungal agents are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

WARNINGS Clotrimazole Topical Solution is not for ophthalmic use.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The following adverse reactions have been reported in connection with the use of clotrimazole: erythema, stinging, blistering, peeling, edema, pruritius, urticaria, burning, and general irritation of the skin. To report SUSPECTED ADVERSE REACTIONS, contact ScieGen Pharmaceuticals, Inc. at 1-855-724-3436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Drug Interactions

openFDA Drug Labeling

Drug Interactions Synergism or antagonism between clotrimazole and nystatin, or amphotericin B, or flucytosine against strains of C. albicans has not been reported.

Description

openFDA Drug Labeling

DESCRIPTION Clotrimazole Topical Solution USP, 1% contains 10 mg clotrimazole USP, a synthetic antifungal agent having the chemical name 1-(o-Chloro-α,α-diphenylbenzyl) imidazole with the following structural formula: Molecular Formula C 22 H 17 ClN 2 Molecular Weight 344.85 Clotrimazole is an odorless, white crystalline substance. It is practically insoluble in water, sparingly soluble in ether and very soluble in polyethylene glycol 400, ethanol, and chloroform. Each mL of Clotrimazole Topical Solution, USP 1% contains 10 mg clotrimazole USP in a nonaqueous vehicle of polyethylene glycol 400. Chemical Structure

OVERDOSAGE Acute overdosage with topical application of clotrimazole is unlikely and would not be expected to lead to a life-threatening situation.

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Clotrimazole Topical Solution, USP 1% is supplied as follows: NDC 50228-502-08 in one 10 mL round bottle in a carton NDC 50228-502-30 in one 30 mL round bottle in a carton NDC 50228-502-31 in one 30 mL oval bottle in a carton Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Adverse event reports

Source: openFDA FAERS
12,736
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: CLOTRIMAZOLE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
71399-0666-3 71399-0666 Akron Pharma Inc. 1 BOTTLE in 1 CARTON (71399-0666-3) / 30 mL in 1 BOTTLE May 4, 2024
71399-0666-6 71399-0666 Akron Pharma Inc. 2 BOTTLE in 1 CARTON (71399-0666-6) / 30 mL in 1 BOTTLE March 25, 2024
71297-030-02 71297-030 Allegis Holdings, LLC 2 BOTTLE in 1 CARTON (71297-030-02) / 10 mL in 1 BOTTLE November 12, 2025
72162-2178-3 72162-2178 Bryant Ranch Prepack 1 BOTTLE in 1 CARTON (72162-2178-3) / 30 mL in 1 BOTTLE July 25, 2019
50228-502-08 50228-502 ScieGen Pharmaceuticals, Inc 1 BOTTLE in 1 CARTON (50228-502-08) / 10 mL in 1 BOTTLE October 16, 2023
50228-502-30 50228-502 ScieGen Pharmaceuticals, Inc 1 BOTTLE in 1 CARTON (50228-502-30) / 30 mL in 1 BOTTLE October 16, 2023
50228-502-31 50228-502 ScieGen Pharmaceuticals, Inc 1 BOTTLE in 1 CARTON (50228-502-31) / 30 mL in 1 BOTTLE October 16, 2023
52817-800-30 52817-800 TruPharma LLC 1 BOTTLE in 1 CARTON (52817-800-30) / 30 mL in 1 BOTTLE July 25, 2019
71399-0666 71399-0666 Akron Pharma Inc. — October 16, 2023
71297-030 71297-030 Allegis Holdings, LLC — November 12, 2025
72162-2178 72162-2178 Bryant Ranch Prepack — July 25, 2019
50228-502 50228-502 ScieGen Pharmaceuticals, Inc — October 16, 2023
52817-800 52817-800 TruPharma LLC — July 25, 2019

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 11 sections on this page.